ライフサイエンスコーパス: menopausal status

1 FFM, or physical activity levels in women by menopausal status.

2 sidered age, smoking, physical activity, and menopausal status.

3 ependent risk contribution from both age and menopausal status.

4 rhea, pre-operative alcohol consumption, and menopausal status.

5 ographic breast density, tumor histology, or menopausal status.

6 an association in women was not explained by menopausal status.

7 dependent of breast density, tumor type, and menopausal status.

8 disease, tumor grade, age at diagnosis, and menopausal status.

9 ic acid; family history of breast cancer; or menopausal status.

10 or status, progesterone receptor status, and menopausal status.

11 hnicity, body mass index, energy intake, and menopausal status.

12 ion or diagnosed high cholesterol level, and menopausal status.

13 ) (OR = 0.50, 95% CI: 0.25, 1.01) instead of menopausal status.

14 isms of sudden coronary death, which vary by menopausal status.

15 human breast carcinogenesis, dependent upon menopausal status.

16 re were significant, they were unaffected by menopausal status.

17 enhancement correlated with patient age and menopausal status.

18 serologic evaluations were used to determine menopausal status.

19 , 95% confidence interval: 0.61, 1.33) or by menopausal status.

20 ll reduction in risk of BC, independently of menopausal status.

21 CVD, but most studies retrospectively assess menopausal status.

22 able to assess effects on body iron, sex, or menopausal status.

23 idermal growth factor receptor 2 (HER2), and menopausal status.

24 in analyses stratified by family history or menopausal status.

25 , tumor characteristics, breast density, and menopausal status.

26 lyses, mostly in subgroups defined by age or menopausal status.

27 rolled for age, total body fat, smoking, and menopausal status.

28 tality from breast cancer, regardless of the menopausal status.

29 ting CSF1 levels and breast cancer varies by menopausal status.

30 cer and reproductive characteristics vary by menopausal status.

31 d 2001, participants provided information on menopausal status.

32 (HRT), and estrogen exposure on the basis of menopausal status.

33 29% were postmenopausal, and 2% were unknown menopausal status; 49.5% were HmR positive; 33.5% were H

34 HER2+/ER- subtype did not vary with race or menopausal status (6%-9%).

35 With menopausal status added to the model, naturally and surg

36 index (BMI); the endometrial model included menopausal status, age at menopause, BMI, smoking, oral

37 use, other MHT use, age at first live birth, menopausal status, age at menopause, family history of b

38 , parity, age at first birth, breastfeeding, menopausal status, age at menopause, use of hormone repl

39 en 1996 and 2001 to determine the effects of menopausal status, age, race, and use of hormone replace

40 sted within strata defined by levels of BMI, menopausal status, alcohol consumption, and C-reactive p

41 This association did not vary by menopausal status, although IBC patients were more likel

42 ciation between persistent mood symptoms and menopausal status and 2) factors that increase a woman's

43 Findings suggest that menopausal status and age at menopause may play a role i

44 Analyses stratified by menopausal status and body mass index also showed no cle

45 no history of depression is associated with menopausal status and changes in reproductive hormones i

46 s annual screen by 10-year age groups and by menopausal status and current postmenopausal HT use.

47 Overall, associations were homogeneous by menopausal status and ER and PR expression in tumors.

48 regression models and stratified analyses by menopausal status and ER/PR status.

49 Subgroup analyses were performed by menopausal status and estrogen receptor (ER) and progest

50 risk and whether the associations varied by menopausal status and estrogen receptor (ER) and progest

51 sical activity in older men and women and in menopausal status and estrogen use in women.

52 rces, season of measurement, and, for women, menopausal status and estrogen use.

53 ber intake and risk of breast cancer (BC) by menopausal status and hormone receptor expression in tum

54 Although menopausal status and hormone replacement therapy use do

55 nges were examined in relation to changes in menopausal status and in levels of estradiol and follicl

56 isk and cancer severity differs according to menopausal status and postmenopausal hormone therapy (HT

57 A significant interaction between menopausal status and treatment group was observed for D

58 ssociation was not significantly modified by menopausal status and was independent of age at menarche

59 oronary artery disease (CAD) is modulated by menopausal status and/or age.

60 ments and adjusted for age, education, race, menopausal status, and baseline reading ability, anxiety

61 e exposure, family history of breast cancer, menopausal status, and body mass index x recent hormone

62 We stratified by smoking, menopausal status, and breast cancer-related variables.

63 iate adjustment for baseline age, ethnicity, menopausal status, and changes in comorbidities and life

64 nd Data System (BIRADS) breast density, age, menopausal status, and current HT use, assuming a body m

65 rian cancer and 116 controls matched on age, menopausal status, and date of blood donation were inclu

66 and left ventricular ejection fraction <55%, menopausal status, and FSH were not associated with BNP

67 s were age, body mass index, blood donation, menopausal status, and HFE genotype.

68 dex, alcohol intake, marital status, parity, menopausal status, and history of myocardial infarction.

69 n, use of lipid-lowering medication, season, menopausal status, and hormone replacement therapy.

70 001) independent of risk factors, age, race, menopausal status, and hormone therapy.

71 ge, race, smoking, blood pressure, diabetes, menopausal status, and hormone use, the odds ratios (95%

72 re in middle-aged men and women by sex, age, menopausal status, and level of obesity, and to compare

73 used as risk stratification tools; and age, menopausal status, and medical comorbidities should be c

74 gitudinally examined the relations of aging, menopausal status, and physical activity to weight and w

75 ucation, age at menarche, pregnancy history, menopausal status, and postmenopausal hormone use, durat

76 by sensitivity to previous hormonal therapy, menopausal status, and presence of visceral metastasis a

77 rmal women matched for age, body-mass index, menopausal status, and race, using dual-energy x-ray abs

78 nd adjusted for body mass index, parity, and menopausal status, and the area under the receiver opera

79 ontrolled for the age of the patients, their menopausal status, and the orientation of the MR images

80 gs from those trials and relate them to age, menopausal status, and tumour oestrogen-receptor concent

81 rvival estimated according to patients' age, menopausal status, and tumour oestrogen-receptor concent

82 sy exists regarding the extent to which age, menopausal status, and/or lifestyle behaviors account fo

83 intake, smoking status, alcohol intake, and menopausal status as potential covariates.

84 a, body mass index [BMI], diabetes mellitus, menopausal status) as well as indicators of systemic inf

85 ; two controls were matched per case on age, menopausal status at blood draw and diagnosis, fasting s

86 se observations did not vary by adult BMI or menopausal status at blood draw.

87 ampsia and breast cancer risk is modified by menopausal status at breast cancer diagnosis.

88 , number of lymph nodes, estrogen receptors, menopausal status at diagnosis, and disease-free interva

89 prognosis and age at menarche and menopause, menopausal status at diagnosis, smoking history, or prio

90 these measures of adiposity vary by age and menopausal status at the time of diagnosis.

91 88 and 1994, was to assess associations with menopausal status based either on menstrual cycle patter

92 smoking, use of hormone replacement therapy, menopausal status, baseline menopausal symptoms, and tre

93 However, age, menopausal status, BMI, and use of hypertensive medicati

94 in pre- and perimenopausal women (i.e., age, menopausal status, body composition, and lifestyle behav

95 ciation did not differ appreciably by stage, menopausal status, body mass index, or estrogen receptor

96 anthropometric and biochemical variables, or menopausal status (breast cancer), higher serum iron con

97 eptor status and age at diagnosis (proxy for menopausal status) by using conditional logistic regress

98 inants of calcium absorption efficiency were menopausal status, calcium intake, and serum estradiol a

99 cent density were evident overall and within menopausal status categories.

100 n, the vascular risk factors increase as the menopausal status changes.

101 After adjustment for age, race, menopausal status, clinical stage, tumor size, and famil

102 rom the entries of patient information (age, menopausal status, comorbidity estimate) and tumor stagi

103 ardiovascular risk status, diuretic use, and menopausal status, confirmed a significant association o

104 Anthropometric measures and menopausal status contribute to a large variability in c

105 definition of the following important terms: menopausal status, CRA (early and late), temporary CRA,

106 The effects of menopausal status, cyst size and other features, and the

107 Menopausal status, cyst size, and other cyst features si

108 urine specimens was one-to-one matched (age, menopausal status, date of urine collection, and day of

109 ER, stage or menopausal status did not modify the effect of post-diag

110 family history remained significant, whereas menopausal status did not.

111 ing factors, including current body size and menopausal status, did not alter the findings.

112 to the patients' axillary lymph node status, menopausal status, disease status, disease-free survival

113 sessed effects of baseline iron status, sex, menopausal status, duration of intervention, iron form,

114 Eligible patients-ie, any menopausal status, Eastern Cooperative Oncology Group pe

115 adjustment for age, alcohol intake, gender, menopausal status, education, body mass index, and pover

116 After adjustment for age, gender, menopausal status, ethnicity, center, smoking, and alcoh

117 database contains information on HRT use and menopausal status for women with a recent MI.

118 trial were similar with respect to age, sex, menopausal status, glucocorticoid dosage and duration, d

119 t and adjusted for number of positive nodes, menopausal status, hormone receptor status, and tumor si

120 = .033), in which analysis was adjusted for menopausal status, hormone receptor status, treatment, n

121 ss index, physical activity, alcohol intake, menopausal status, hormone replacement therapy, aspirin

122 of asthma and respiratory symptoms differ by menopausal status in a longitudinal population-based stu

123 cross-sectional differences in MD by age and menopausal status in over 11,000 breast-cancer-free wome

124 whether breast cancer risk varies by age and menopausal status in relation to use of hormonal birth c

125 To examine the effect of menopausal status in the absence of data on individual p

126 The relative contribution of age versus menopausal status in the development of CAD in women rem

127 We attempted to (1) define menopausal status in the setting of adjuvant chemotherap

128 older adulthood (ages >/=70 years); or 2) by menopausal status in women and stratification by age 50

129 , HDL and LDL cholesterol, R-R interval, and menopausal status in women showed QTc and JTc were nonpr

130 tratified by gender and further according to menopausal status in women.

131 gy intake, physical activity, education, and menopausal status (in women).

132 Within-woman change in menopausal status, increased levels of follicle-stimulat

133 Age, rather than menopausal status, independently contributed to damage a

134 The authors assessed age, menopausal status, index breast cancer histologic result

135 hypertensive, with information on ethnicity, menopausal status, insulin-resistant status, and 21 loci

136 sus menopausal status, we fit a hypertension-menopausal status interaction term and adjusted for age.

137 Age rather than menopausal status is a strong independent predictor of d

138 Assessment of menopausal status is critical; ovarian suppression or ab

139 stolic, and pulse pressure, body mass index, menopausal status, levels of total and low-density lipop

140 l groups (patients matched for age, sex, and menopausal status), made comparisons with established da

141 se subjects (n = 1108) and age-, gender- and menopausal status-matched participants in the Framingham

142 Neither sex nor menopausal status may be relevant in antidepressant trea

143 Subject characteristics (eg, menopausal status) modulated the dietary requirement for

144 When stratified by menopausal status, no noteworthy associations were obser

145 sociated with grade, but not associated with menopausal status, nodal status, or tumor size.

146 nonresponders were not distinguished by age, menopausal status, nor several cephalometric or anthropo

147 s by age, age at menarche, age at menopause, menopausal status, number of pregnancies, breast feeding

148 Analyzing data without regard to sex or menopausal status obscured group differences in circuit-

149 interactions between MAF-positive status and menopausal status on efficacy of zoledronic acid.

150 Effects of menopausal status on grip and pinch strength did not var

151 However, the effect of risk factors and menopausal status on the mechanism of sudden coronary de

152 association might not vary substantially by menopausal status or estrogen receptor status.

153 iation, either overall or when stratified by menopausal status or hormone receptor status.

154 etween the two cohorts might be explained by menopausal status or simply by chance.

155 No meaningful difference was seen by menopausal status or type of beverage consumed.

156 FN after adjustment for age, weight, height, menopausal status or use of hormone replacement therapy,

157 t differ according to age, CVD risk factors, menopausal status, or anticancer treatment.

158 t modified or confounded by body mass index, menopausal status, or caloric intake during the past yea

159 ot vary by alcohol intake, multivitamin use, menopausal status, or oral contraceptive use.

160 erences in smoking history, body mass index, menopausal status, or personal or family history of cent

161 tected was not influenced by breast density, menopausal status, or the histologic features of the pri

162 not vary by body mass index, smoking status, menopausal status, or time between urine collection and

163 B-14 through 15 years, irrespective of age, menopausal status, or tumour oestrogen-receptor concentr

164 m the bed or used throughout the night; with menopausal status; or with the cases' hormone receptor s

165 oking, parity and duration of breastfeeding, menopausal status, oral contraceptive use, body mass ind

166 Exogenous estrogen use (P < .001) and menopausal status (P = .007) correlated significantly wi

167 for node status, tumor size, treatment, and menopausal status (P = 0.005 and P < 0.001, respectively

168 .6; P for trend = .002), and did not vary by menopausal status (P for interaction = .95).

169 The association varied by menopausal status (P(heterogeneity) = 0.009).

170 Because choline needs vary by age, sex, and menopausal status, participants were segregated into cor

171 and c-erbB-2 status) and patient parameters (menopausal status, personal history of breast carcinoma)

172 ng, oral contraceptive use, body mass index, menopausal status, postmenopausal hormone therapy use, d

173 case were randomly chosen, matched for age, menopausal status, postmenopausal hormone use, and day,

174 ny), adjuvant chemotherapy (none v any), and menopausal status (pre-, peri-, or postmenopausal).

175 tus [one to three v > three positive nodes], menopausal status [pre- v postmenopausal women], estroge

176 oost or no boost, with minimisation for age, menopausal status, presence of extensive ductal carcinom

177 PE demonstrated significant association with menopausal status, prior breast radiation therapy, hormo

178 Knowledge of menopausal status, prior chemotherapy, and ESR genotype

179 ty, education, smoking, parity, anxiety, and menopausal status (relative to stable body fat, gain: od

180 Further stratification by menopausal status resulted in the same conclusion.

181 the absence of data on individual patients' menopausal status, results for female patients younger o

182 Both gender and menopausal status should be considered when choosing an

183 Comparison of treatment response rates by menopausal status showed that premenopausal women respon

184 results were found after adjusting for age, menopausal status, smoking habit, and sexual exposure hi

185 ls; investigated effect modification by sex, menopausal status, smoking, and age; and calculated popu

186 These results were independent of age, menopausal status, smoking, diabetes, hypertension, and

187 OR(Q4) = 0.5, (0.3, 0.8), adjusted for age, menopausal status, soy protein, fibroadenoma history, fa

188 status, type and timing of systemic therapy, menopausal status, statin use, and treating centre.

189 status, type and timing of systemic therapy, menopausal status, statin use, and treatment centre) to

190 years for sociodemographic characteristics, menopausal status, surgeries, body mass index, medicatio

191 Risk estimates did not vary by menopausal status, tumor invasiveness, or estrogen recep

192 In a model that included age, race, obesity, menopausal status, tumor size, nodal status, treatment a

193 body mass index, lifetime physical activity, menopausal status, use of estrogen, and smoking.

194 iates (age, season of vitamin D measurement, menopausal status, use of hormone replacement therapy, a

195 ive factors (ages at menarche and menopause, menopausal status, use of oral contraceptives, and menop

196 formation on menstrual patterns to determine menopausal status using latent class analysis.

197 Menopausal status was associated with accelerated lung f

198 Menopausal status was defined as nonmenopausal, transiti

199 Menstrual cycle-based menopausal status was defined for women who had not had

200 Menopausal status was determined from menstrual history,

201 , a significant interaction of WSHT group by menopausal status was found for systolic blood pressure

202 Change in menopausal status was not associated with weight gain or

203 When matched the participants by age, post-menopausal status was still associated with a higher ris

204 sess the relative contribution of age versus menopausal status, we fit a hypertension-menopausal stat

205 Increasing age and post-menopausal status were associated with the presence of t

206 Physical activity levels and menopausal status were included as covariates.

207 This association is independent of menopausal status, which remains an independent predicto

208 d 1,493 controls aged 20-98 years with known menopausal status, who had participated in a population-

209 ntrols, apart from a modest association with menopausal status with an increased risk of 1.53 and 1.4

210 ast cancer are associated with the patient's menopausal status, with a typical kinetic pattern of mal

211 tion between the kinetic characteristics and menopausal status, with an odds ratio of 2.94 for the la

212 garette smoking, diabetes, vascular disease, menopausal status (women only), and age.

213 ge, smoking, postmenopausal hormone use, and menopausal status, women with increased BMI (> or =27 kg

214 xamined cross-sectionally the association of menopausal status, years since last menstruation, and ho